Akouos IPO Presentation Deck

AK-antiVEGF for the Treatment of Vestibular Schwannoma Human Data Demonstrate Ability of Systemic VEGF Inhibitor to Improve Hearing and Reduce Tumor Volume in Some Patients with Vestibular Schwannomas The NEW ENGLAND JOURNAL MEDICINE 39 Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2 ORIGINAL ARTICLE S Neuro-Oncology 12(1):14-18, 2010 dox 10.1093/neuonc nopo10 Fre Advance Access publication October 20, 2009 Al Victor-Felix Carsten Bo NEURO-ONCOLOGY Bevacizumab induces regression of vestibular schwa neuro 10.1007/11060015-1828-8 CLINICAL STUDY Department Bevacizumab decreases vestibular schwannomas growth rate Neuropatholo Center Man in children and teenagers with neurofibromatosis type 2 Audrey Hochart- Vianney Gaillard-Mare Baroncini Nicolas Andre Jean-Pierre Vannier Matthieu Vinchon Frederique Dubrulle². Jean-Paul Lejeune-Christophe Vincent Véronique Neve Hélène Sudour Bonnange Nicolas Xavier Bonne" - Pierre Leblond CONFIDENTIAL Preliminary Data Demonstrate Delivery of AK-antiVEGF Results in Therapeutic Protein Expression with Preserved Anatomy and Physiology in Mice and NHPs Percent Missing Cells (Normalized) AAVAnc80-antiVEGF in Mouse ABR Threshold Shift in NHP Anti-VEGF and Actin Anti-VEGF 8 3 8 2 8 8 10 40 30 20 10 0 -20 -30 -40 AKQUOS Molith 15 Distance from Apex (mm) Month 2 NHP Cytocochleogram 2 months after AK-antiVEGF Delivery Cell Types AVG_OHC IHC Month3 20

View entire presentation